Aeterna Zentaris (AEZS)

Aeterna Zentaris (AEZS) Stock Price & Analysis


AEZS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.32 - $8.65
Previous Close$2.78
Average Volume (3M)15.66K
Market Cap
Enterprise Value$13.50M
Total Cash (Recent Filing)$322.00K
Total Debt (Recent Filing)$179.00K
Price to Earnings (P/E)-0.6
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding4,855,876
10 Day Avg. Volume8,431
30 Day Avg. Volume15,659
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)-0.07
Price to Sales (P/S)2.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.43
Enterprise Value/Gross Profit-1.61
Enterprise Value/Ebitda-1.81
Price Target Upside909.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Aeterna Zentaris’s price range in the past 12 months?
Aeterna Zentaris lowest stock price was $2.32 and its highest was $8.65 in the past 12 months.
    What is Aeterna Zentaris’s market cap?
    Currently, no data Available
    When is Aeterna Zentaris’s upcoming earnings report date?
    Aeterna Zentaris’s upcoming earnings report date is Aug 10, 2023 which is in 69 days.
      How were Aeterna Zentaris’s earnings last quarter?
      Aeterna Zentaris released its earnings results on May 09, 2023. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$1.07 by $0.19.
        Is Aeterna Zentaris overvalued?
        According to Wall Street analysts Aeterna Zentaris’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aeterna Zentaris pay dividends?
          Aeterna Zentaris does not currently pay dividends.
          What is Aeterna Zentaris’s EPS estimate?
          Aeterna Zentaris’s EPS estimate is -$0.87.
            How many shares outstanding does Aeterna Zentaris have?
            Aeterna Zentaris has 4,855,876 shares outstanding.
              What happened to Aeterna Zentaris’s price movement after its last earnings report?
              Aeterna Zentaris reported an EPS of -$0.88 in its last earnings report, beating expectations of -$1.07. Following the earnings report the stock price went down -1.29%.
                Which hedge fund is a major shareholder of Aeterna Zentaris?
                Currently, no hedge funds are holding shares in AEZS


                Aeterna Zentaris Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Aeterna Zentaris

                Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Aethlon Medical
                CTI BioPharma
                Fate Therapeutics
                Infinity Pharma

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis